Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telitacicept in Lupus Nephritis
NCT05680480Phase 2Recruiting
- Sponsor
- RemeGen
- Start
- Apr 2023
- Primary completion
- Dec 2025
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of telitacicept in lupus nephritis (LN) (3 arms), sponsored by RemeGen. Primary endpoint: Complete Renal Response at Week 48. Started Apr 2023; status: recruiting.
02
Drugs
telitacicept
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on NCT05680480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05680480.